Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06831968 · ClinicalTrials.gov registry record
Clinical Validation of a Predictive Test for Postpartum Depression
A clinical trial of Pregnancy and Postpartum Depression (PPD), sponsored by University of Virginia.
- Recruiting
- Registry status
- 500
- Enrollment target
- 2
- Study locations
NCT06831968 is a study of Pregnancy and Postpartum Depression (PPD) that is actively recruiting participants, run by University of Virginia. The registered enrollment target is 500 participants, below the 870-participant average among 191 other Pregnancy trials with a reported enrollment target (43% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT06831968, a study of Pregnancy and Postpartum Depression (PPD), is actively recruiting participants, sponsored by University of Virginia.
- RECRUITING
- Registry status
- 500 participants
- Enrollment target
- 2
- Study locations
Study Summary
The goal of this observational study is to develop a blood test that may be predictive of postpartum depression. This Blood test is investigational and not yet FDA approved. Participants will not receive the results of this blood test. Up to 500 pregnant women will be recruited for the study from 2 sites. Participants must be age 18 or above with a singleton pregnancy and able to provide written consent in English. The Objective of this Clinical Trial is to prospectively validate the Enlighten Device test by prospectively determining false/true positive and negative rates. Building off of this, an exploratory objective of this study is to examine clinical factors associated with false positive/negative rates. This project will address the following Aim: Aim 1: Prospective collection of true/false positive and negative PPD outcomes through 6 months postpartum. Primary Hypothesis H1a: 80% or greater of pregnant women who develop PPD by 3 months after delivery will be determined to be Biomarker Positive by the Enlighten Device in T3. Primary Hypothesis H1b: 10% or fewer of pregnant women who are determined to be Biomarker Negative by the Enlighten Device in T3 will develop PPD by 3 months after delivery. Exploratory Aim 1: Investigation of clinical factors that may be associated with false positive and false negative rates, such as: medication use, stressful life events, and sociocultural context. Participants will be screened during the second or third trimester and enrolled during the third trimester, before week 30 weeks of gestation. Participants may self- identify through study advertisements in participating clinics, social media outlets, and community outreach efforts. Enrolled participants will undergo blood collection during their 3rd trimester (\~27-30 weeks, a standard pregnancy-related blood collection timepoint) for completion of the Enlighten Device test, the blood-based epigenetic biomarker test. Participants will then be interviewed at 2 weeks,
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Enlighten
Study Locations (2)
Virginia
- University of Virginia - Charlottesville
- Inova Health System - Falls Church
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2025-03-20 |
| Est. Completion | 2028-07-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06831968
The ClinicalTrials.gov registry entry for NCT06831968 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 870-participant average among 191 other Pregnancy trials with a reported enrollment target (43% lower). The listed sponsor is University of Virginia, which has 449 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Pregnancy appearing as the primary indexed condition, and to 1 intervention - of which Enlighten is the first listed.
NCT06831968 reports 2 study locations spanning 1 distinct geographic area - top geographies include Virginia.
Frequently Asked Questions
What is clinical trial NCT06831968 about?
NCT06831968 is a clinical study titled "Clinical Validation of a Predictive Test for Postpartum Depression". The goal of this observational study is to develop a blood test that may be predictive of postpartum depression. This Blood test is investigational and not yet FDA approved. Participants will not receive the results of this blood test. Up to 500 pregnant women will be recruited for the study from 2...
What is the current status of trial NCT06831968?
This trial is currently recruiting. The enrollment target is 500 participants. The study started on 2025-03-20. Estimated completion is 2028-07-31.
What conditions does trial NCT06831968 study?
This clinical trial studies the following conditions: Pregnancy, Postpartum Depression (PPD).
What interventions are being tested in trial NCT06831968?
The interventions under investigation include: Enlighten (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06831968?
This trial is sponsored by University of Virginia, which has 449 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06831968 being conducted?
This trial has 2 study locations across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pregnancy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Stelara and Tremfya Pregnancy Exposure Registry OTIS Autoimmune Diseases in Pregnancy Project
RECRUITING
-
CGM Adherence Compared to Finger-stick Glucose Monitoring in Pregnancies With Type 2 Pregestational Diabetes
RECRUITING · NA
-
Healthy Start: Exploring the Fuel-mediated Programming of Neonatal Growth
RECRUITING
-
Cocooned Moms Study
RECRUITING · NA
-
Retinal Vascular Changes During Pregnancy
RECRUITING
-
CGM for Management of Type 2 Diabetes in Pregnancy
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.